Arcturus Therapeutics has been granted a patent for nucleic acid molecules that encode viral replication proteins and antigenic proteins. These molecules can be used to induce immune responses and are included in compositions with lipids. The patent also includes a claim for a specific nucleic acid molecule that is codon-optimized and has a high identity to a specific sequence. GlobalData’s report on Arcturus Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Arcturus Therapeutics, Nanoparticle drug conjugates was a key innovation area identified from patents. Arcturus Therapeutics's grant share as of September 2023 was 33%. Grant share is based on the ratio of number of grants to total number of patents.
Patent granted for nucleic acid molecules encoding viral proteins
A recently granted patent (Publication Number: US11759515B2) describes a nucleic acid molecule that can be used to induce an immune response to specific antigenic proteins in a subject. The molecule consists of two components: a first polynucleotide encoding viral replication proteins and a second polynucleotide encoding an antigenic protein or a fragment thereof. The first polynucleotide is codon-optimized and has at least 80% identity to a specific sequence.
The nucleic acid molecule may also include a 5' untranslated region (UTR) with an alphavirus 5' UTR sequence and a 3' untranslated region (UTR) with an alphavirus 3' UTR sequence, which may include a poly-A sequence or a specific sequence.
The antigenic protein can be a viral protein, bacterial protein, fungal protein, protozoan protein, parasite protein, or tumor protein. Examples of specific viral proteins include those from orthomyxoviruses, paramyxoviruses, picornaviruses, flaviviruses, filoviruses, rhabdoviruses, togaviruses, arteriviruses, bunyaviruses, arenaviruses, reoviruses, bornaviruses, retroviruses, adenoviruses, herpesviruses, polyomaviruses, papillomaviruses, poxviruses, and hepadnaviruses.
The nucleic acid molecule may also include multiple transgenes encoding different antigenic proteins, immunomodulatory proteins, or reporter proteins. These transgenes can be separated by a sequence encoding a 2A peptide, an internal ribosomal entry site (IRES), a subgenomic promoter, or a combination thereof.
The nucleic acid molecule can be in the form of a DNA molecule or an RNA molecule, with T substituted with U in the RNA molecule. The DNA molecule may include a promoter such as a T7 promoter, a T3 promoter, or an SP6 promoter. The RNA molecule can be self-replicating and may have a 5' cap structure.
The patent also covers a pharmaceutical composition containing the nucleic acid molecule and a lipid formulation, particularly one with an ionizable cationic lipid.
Methods of inducing an immune response to an antigenic protein in a subject are also described. These methods involve administering an effective amount of the nucleic acid molecule or the pharmaceutical composition to the subject.
Overall, this patent provides a novel approach for inducing immune responses to specific antigenic proteins, potentially leading to the development of new vaccines and therapies.
To know more about GlobalData’s detailed insights on Arcturus Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
